Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...

Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio said they will not be involved with activist investor Starboard Value, ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Pfizer's shares have fallen more than 9% in the past year and trade at around half of their pandemic-era highs as sales of ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

Pfizer in recent months has implemented aggressive cost-cutting measures to help it weather the steep decline in sales of its ...

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 fourth-quarter 2024 dividend on the ...

An activist invester has taken interest in pharma giant Pfizer, which despite becoming a household name during the pandemic ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.